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ADA: Adenosine deaminase
DBS: Dried blood spot
SCID: Severe combined immunodeficiency
TREC: T-cell receptor gene excision circleBackground: Adenosine deaminase (ADA)–severe combined
immunodeficiency (SCID) is an SCID caused by a defect in the
enzyme adenosine deaminase. It is usually fatal in infancybecause
of severe recurrent infections. When diagnosis is made,
permanent damage caused by infections or bymetabolites is often
present. Gene therapy, bone marrow transplantation, or enzyme
therapy might be effective if performed early. ADA-SCID
complies with all the criteria for inclusion in a newborn screening
program. However, screening methods are still expensive or
provide a non-negligible number of indeterminate results.
Objective: The aim of the present study was to develop a simple,
reliable, and inexpensive method for diagnosis of ADA-SCID by
using dried blood spot (DBS) samples taken at birth. Cost per
test was calculated, including the cost for reagents, equipment,
and operators.
Methods: DBS samples from 4 patients with genetically
confirmed ADA-SCID and 12,020 DBS samples from healthy
newborns were examined. Adenosine and 29-deoxyadenosine
were tested by using tandem mass spectrometry (PCT EP2010/
070517).
Results: The mean levels of adenosine and 29-deoxyadenosine
were 7.8 6 3.1 and 8.5 6 6.0 mmol/L, respectively, in affected
children; adenosine was found at 0.23 6 0.09 mmol/L, whereas
29-deoxyadenosine was never detected in healthy control
subjects (adenosine: P < 1026 [95% confidence limit, 7.59-7.78]
and 29-deoxyadenosine: P < 1026 [95% confidence limit,
8.65-8.82] for control subjects vs patients with ADA-SCID). No
indeterminate or false-positive results were found. Cost per test
was V0.01 ($0.013). A pilot population-based newborn screening
for ADA-SCID has started in Tuscany, Italy.
Conclusion: Tandem mass spectrometry can be used for
diagnosis of one of the most frequent form of SCID at a
negligible cost. (J Allergy Clin Immunol 2011;127:1394-9.)
Key words: Adenosine deaminase, severe combined immunodefi-
ciency, newborn screening, tandem mass spectrometryFrom the Departments of aPediatrics and cPharmacology, University of Florence, and
bAnna Meyer Children’s University Hospital, Florence.
All of the authors contributed equally to this work.
Supported in part by a donation from Famiglia Cassigoli (C.A.) and by a grant from the
University of Florence (C.A. and G.l.M.) and Anna Meyer Children’s University
Hospital (M.R.) and the Tuscany (Italy) region (C.A., G.l.M., and M.R.).
Disclosure of potential conflict of interest: G. La Marca receives research support from
the Tuscany Region, Italy. The rest of the authors have declared that they have no
conflict of interest.
Received for publication January 4, 2011; revised February 18, 2011; accepted for pub-
lication March 24, 2011.
Reprint requests: Chiara Azzari, MD, PhD, Department of Pediatrics, University of
Florence, Anna Meyer Children’s University Hospital, Viale Pieraccini, 24,
50139 Firenze, Italy. E-mail: chiara.azzari@unifi.it.
0091-6749/$36.00
 2011 American Academy of Allergy, Asthma & Immunology
doi:10.1016/j.jaci.2011.03.040
1394Severe combined immunodeficiency (SCID) is a group of
severe diseases that affect the immune system. Infants with SCID
are healthy at birth but die of severe infections in infancy unless
adequate therapy is provided.1-3 Unfortunately, almost all infants
with SCID are not identified in the preinfection period; when the
diagnosis is hypothesized, usually a severe infection has just oc-
curred. At that time, however, even though a correct therapeutic
intervention is started, damages caused by the severe infections
(eg, meningitis, encephalitis, and severe pneumonia) can already
be present,1,3 and permanent sequelae can be an important burden
both for patients and families, as well as for the society.Moreover,
cases in which children die of severe infection before diagnosis of
SCID is made are not infrequent.
Adenosine deaminase (ADA) deficiency is a fatal autosomal
recessive form of SCID caused by an inherited disorder of purine
metabolism.4 ADA is an enzyme of the purine salvage pathway
that catalyzes the deamination of adenosine and 29-deoxyadeno-
sine to inosine and 29-deoxyinosine, respectively. In the typical
form (neonatal onset, 85% to 90%) of ADA deficiency, absence
of the enzyme and accumulation of toxic metabolites are present.
The classical phenotype includes a severe defect of the immune
system with the absence of both cellular and humoral immunity
and permanent damage to other organs and systems, such as the
brain or liver.4,5 In these cases ADA-SCID is usually fatal within
the first months of life in untreated patients and is associated with
severe sequelae in those who are treated late. Unlike many other
forms of SCID, the systemic nature of ADA expression also re-
sults in nonimmunologic abnormalities in a significant proportion
of children who might have neurodevelopmental defects, sensori-
neural deafness, and/or skeletal abnormalities.6 Systemic mani-
festations are frequent, and their severity is proportionate to
blood and urine levels of metabolites and to age at diagnosis.
The incidence of ADA deficiency is estimated to be between
1 in 375,000 and 1 in 660,000 live births4 and accounts for around
15% to 20% of all SCID cases. However, the incidence of the dis-
ease is probably underestimated because of early deaths caused
by infections and might be higher in specific ethnic groups world-
wide, especially where the rate of consanguinity is high.7 Enzyme
replacement therapy, hematopoietic stem cell transplantation, or
gene therapy might be curative, but their efficacy is dependent
on the early approach.8 Whichever therapy is chosen, it should
be started as soon as possible after birth to obtain the best thera-
peutic effect through a rapid metabolic detoxification. In children
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tional to the age when transplantation is done.4,8
At present, diagnostic methods are still aimed to uncover
evidence of ADA toxic metabolites in urine or a defect in ADA
activity in blood obtained by means of venipuncture.9 Other
methods have been described, but most of them have in common
the application in children in whom the diagnosis is already
hypothesized and clinical symptoms are already present. On the
contrary, affected infants should receive diagnoses before the
onset of infection to maximize the opportunity for life-saving
treatment. Therefore a population-based newborn screening
program could be the correct approach.
It has been demonstrated that the absence of T-cell receptor gene
excision circles (TRECs) could identify infants with SCIDby using
DNA from dried blood spot (DBS) samples collected for screening
newborns1; however, as described by the authors, those methods
still have a non-negligible number of indeterminate tests and a
cost (>$5 per test) that might be unaffordable in many countries.
Expanded newborn screening by means of tandem mass
spectrometry has grown from the analysis of a few tens of
thousands of samples from Western Pennsylvania in 1992 to
nearly 4 million in the United States in 2008 and millions more
throughout theworld.10 In Tuscany (Italy), officially mandated by
a legislative action, the program has screened all babies born since
November 2004 (approximately 40,000/y) for selected acylcarni-
tines and amino acids.11
The aim of the present work was to set up a simple and
inexpensive method of working with DBS samples taken at birth
for other newborn screening to detect ADAmetabolites with high
sensitivity and specificity.METHODS
Guthrie card collection procedure
DBS samples are routinely collected from all neonates born in Tuscany
(about 40,000/y). Blood collection (4 DBSs on a Guthrie card) is recom-
mended for between 48 and 72 hours of life. Blood samples are obtained by
means of heel stick, spotted on filter paper (903; Whatman GmbH, Dassel,
Germany), dried, and sent daily by courier to the central newborn screening
laboratory. An expanded newborn screening is routinely performed, including
hypothyroidism, cystic fibrosis, biotinidase deficiency, and more than
40 inborn errors of metabolism of amino acids, organic acids, and fatty acids.
All Guthrie card are analyzed within 2 days from collection; after use, all
cards are stored and, if not used, discarded after 10 years.Tandem mass spectrometry
An ABI SCIEX (Toronto, Canada) API 2000 bench-top Triple-Quad Mass
Spectrometer equipped with the turbo ion spray sourcewas used for this study.
The turbo ion spray source operated under positive ion mode at a voltage of
5500 V and a ‘‘turbo’’ gas flow of 10 L/min of air heated to 3508C (nominal
heating-gun temperature).
Mass calibration and resolution adjustments on the resolving quadrupoles
were performed automatically by using a polypropylene glycol 1027 mol/L
solution introduced through the built-in infusion pump. The resolution was
set on both resolving quadrupoles at 0.7 atopic mass units (measured at one
half height) for all mass spectrometric and tandem mass spectrometric
experiments.
Collision-activated dissociation tandemmass spectrometry was performed
through the LINAC Q2 collision cell, operating with 10 milliTorr pressure of
nitrogen as collision gas.
Declustering potential, collision exit potential, and collision energy were
automatically optimized for adenosine, deoxyadenosine, ribose-1-13C-adenosine, and 13C5 deoxyadenosine by using the quantitation optimization
option. the resulting declustering potential was 170 V. Optimal collision en-
ergy and collision exit potential were found at 26 and 20 V, respectively.
Mass spectrometric and tandem mass spectrometric spectra were collected
in continuous-flowmode by connecting the infusion pump directly to the turbo
ion spray source. Standard solutions of 1 ng/mL adenosine, deoxyadenosine,
ribose-1-13C-adenosine, and 13C5 deoxyadenosine in an aqueous solution of
50% methanol containing 0.1% formic acid were infused at 10 mL/min.
From these experiments, the resulting ion-pair transitions for the quantitative
experiment are as follows: 268.2 > 136.1 and 269.2 > 136.1 for adenosine and
ribose-1-13C-adenosine, respectively, and 252.2 > 136.1 and 257.2 > 136.1 for
deoxyadenosine and 13C5 deoxyadenosine, respectively.Guthrie cards from patients with ADA-SCID and
control subjects
DBS samples from 4 patients with genetically confirmed early-onset ADA-
SCID (1 month, 4 months, 4 years, and 6 years old, respectively) were
evaluated. Three of themwere born and resident in Tuscany, and the forth was
born in a different region but referred to our hospital for immunologic
evaluation. DBS samples had been obtained as previously described and tested
for individuation of ADA metabolites with an API 2000 Tandem Mass
Spectrometer (Applied Biosystems, Foster City, Calif).
As controls, DBS samples from 12,020 healthy newborns (10,960 full-term
and 1,060 premature infants weighing <1,500 g) from the same region and
collected in the years 2005 to 2009 were also analyzed. Informed consent was
obtained from parents or guardians. The study was approved by the local
institutional review board.Sample preparation
Sample preparation for routinely screening tests is exactly as reported by la
Marca et al12 in 2008, with the exception of the butylation procedure, which is
not carried out.Method validation
The method for individuating ADA metabolites on DBS samples has been
patented (PCTEP2010/070517). Themethod provides quantitative analysis of
different metabolites, among them adenosine and deoxyadenosine. The cutoff
of the test is 0.005 mmol/L for any of the 2 analytes.
Reference standard blood (whole blood) spots were prepared by using a
pooled whole-blood sample obtained from 5 subjects. The blood was
processed by adjusting the hemoglobin concentration to 17 mg/dL and adding
adenosine and deoxyadenosine at known concentrations. The processed blood
was dispensed onto filter paper cards to form blood spots on the filter paper
matrix. Each blood spot was generated by dispensing 25 mL of processed
blood. The blood spots were allowed to dry overnight.
A small disc (3.2 mm) of a DBS was punched and deposited in a well of a
microwell plate. The sample was extracted by dispensing 300 mL of an
extraction solution consisting of a mixture of methanol and aqueous
solution of 3 mmol/L hydrate hydrazine at an approximate relative
volume/volume ratio of 66.6% and 33.3%, respectively. Internal standards,
stable heavy isotope analogs of several amino acids, carnitine, acylcarni-
tines, succinylacetone, adenosine, and deoxyadenosine, were also present in
the extract solution.
The extracted sample was injected into an electrospray triple quadrupole
tandemmass spectrometer with the aid of an automated liquid-handling device.
Mass spectral data for the amino acids were acquired through a neutral loss scan
of 46 Da; mass spectral data for the acylcarnitines were acquired through a
precursor ion scan of 85 Th. Mass spectral data for adenosine, deoxyadenosine,
and succynilacetone were acquired through multiple-reaction monitoring.
The percentage of each analyte recovered was determined through comparison
with an internal standard for each analyte.
The imprecision of the assay was determined by analyzing the samples
described in Table I. Each sample run consisted of sextuplicate punches of
each sample, which were processed and measured as described. The study
TABLE I. Results of the imprecision assay for adenosine and
deoxyadenosine detection in DBS samples: imprecision within
run, between runs, within day, and between days
Intraday Interday Average
J ALLERGY CLIN IMMUNOL
JUNE 2011
1396 AZZARI, LA MARCA, AND RESTIincluded 6 such runs a day for a total of 6 days. With this information, the
imprecision components of within run, between run/within day, and between
day were determined, from which the total imprecision was determined. The
results of the imprecision analysis of adenosine and deoxyadenosine are
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Adenosine 0 0 0.0 0.0
Adenosine 33 3.5 3.1 34.0 103.1
Adenosine 165 4.9 3.7 158.0 95.8
Adenosine 330 7.8 6.0 336.2 101.9
Adenosine 3300 3.8 4.8 3299.7 100.0
Adenosine 6600 2.1 2.6 6594.2 99.9Cost analysis
Costs for reagents, equipment, and laboratory operators have been
considered to evaluate the total cost of the test per patient. Costs of Guthrie
cards and transport to the newborn screening laboratory were not included
because the test was performed on the same Guthrie card already used for all
other neonatal screening routinely performed in Tuscany.
Adenosine 9900 2.3 2.0 9899.9 100.0
Deoxyadenosine 0 0 0.0 0.0
Deoxyadenosine 33 19.6 16.9 32.8 92.9
Deoxyadenosine 165 6.6 4.8 169.6 100.3
Deoxyadenosine 330 5.2 3.6 325.4 100.6
Deoxyadenosine 3300 5.6 6.7 3300.2 100.3
Deoxyadenosine 6600 3.4 3.4 6599.2 100.0
Deoxyadenosine 9900 3.1 3.1 9904.9 100.0RESULTS
Sensitivity and specificity of the test
All the DBS samples obtained in the first days of life from the
4 patients with ADA-SCID demonstrated high levels of adenosine
and 29-deoxyadenosine. In the patients the mean 6 SD levels of
adenosine and 29-deoxyadenosine were 7.8 6 3.1 and 8.5 6 6.0
mmol/L, respectively, and ranged between 4.4 and 11.8 mmol/L
for adenosine and 2.5 and 16.2 mmol/L for 29-deoxyadenosine
(Fig 1). 29-Deoxyadenosine was never detected in any of the
12,020 healthy control samples, whereas adenosine had a mean
6 SD level of 0.23 6 0.09 mmol/L and ranged between
0.01 and 0.81 mmol/L, with a median of 0.21 mmol/L (P <
1026; 95% confidence limit, 7.59-7.78 vs patients with ADA-
SCID) and no difference between full-term or premature infants.
No false-positive or indeterminate test results were found.
As for adenosine, the ratio between the mean level in children
with ADA-SCID and control subjects was 34.0, whereas for
29-deoxyadenosine, the ratio was incalculable because of the
absence of 29-deoxyadenosine in healthy subjects. However,
hypothesizing a mean level equal to the cutoff (0.005 mmol/L)
in healthy newborns, the ratio between children with ADA-
SCID and healthy children would be 1700 for that analyte
(P < 1026; 95% confidence limit, 8.65-8.82 vs patients with
ADA-SCID).Costs per patient
No extra operator timewas necessary for sample preparation or
sample analysis beside the time necessary for routine neonatal
screening. Similarly, no instrumentation was necessary beside
that routinely used for neonatal screening, and the instruments
were not used for longer times. Therefore the cost was calculated
for reagents only. The cost wasV0.006 per patient (5 $0.0078 on
September 22, 2010). Reagent waste during dilution, aliquot
preparation, and sampling is usually unavoidable, and therefore
the cost per patient was rounded up to V0.01 ($0.013).DISCUSSION
The results of the present study demonstrate that patients with
ADA-SCID can easily have their disease diagnosed at birth by
using the same method (tandem mass spectrometry) already used
for neonatal screening and with a cost of V0.01 per patient.
As with other SCIDs, patients with ADA-SCID have severe and
often fatal infections if they remain untreated and might have
permanent sequelae if treated late. Clinical features of ADA-
SCID are those that are considered necessary to include a diseasein a neonatal screening program: high mortality and morbidity of
the disease, which could be cured if recognized early, and the
availability of a simple and inexpensive test able to individuate
disease markers.
Recently, a statement of the Advisory Committee on Heritable
Disorders in Newborns and Children13 has underlined the impor-
tance of screening programs for immunodeficiencies.
As suggested,1 progressing from conception to implementation
of neonatal screening requires positive answers to many questions
regarding sensitivity and specificity, performance for large-scale
use, and possible limitation to a special subpopulation. Indeed,
although screening must be highly sensitive not to miss all true
cases, specificity is also very important to avoid expenses associ-
ated with unneeded follow-up.
The method we describe, even though performed as a pilot
study in 4 patientswithADA-SCIDand in a limited group of about
12,000 healthy control subjects, seems to be promising. First, it is
able to detect the analyte without overlapping between newborns
with ADA-SCID and control subjects, with mean values in
patients that were more than 30 times higher for adenosine and
more than 1,700 times higher for 29-deoxyadenosine. Moreover,
the test had no false-positive results, and the large difference in the
measured ranges between patients and control subjects makes it
useless to use any algorithm to predict true positivity. The absence
of follow-up visits or blood examinations because of false-positive
results further increases cost-effectiveness.
ADA-SCID screening by means of tandem mass spectrometry
fromDBS samples could be easily included in a population-based
screening program because of its low cost and because it does not
require extra instrumentation or extra time for operators already
working in screening programs. This is an important point
because policymakers consider,14 as a primary topic, whether a
sufficient public health infrastructure exists to support the new
test. Actually, different from screening based on TRECs, which
requires a laboratory with the ability to perform quantitative
PCR (a technique that currently is not used in most newborn-
screening programs),15 screening based on tandem mass spec-
trometry can be immediately performed in laboratories working
on newborn screening.
FIG 1. Histograms of metabolite (adenosine and 29-deoxyadenosine) concentration in a patient with
ADA-SCID and a representative control subject. Adenosine and 29-deoxyadenosine levels of a patient with
ADA-SCID (right) and a representative healthy control subjects (left), as obtained fromDBS samples taken at
birth, are shown. Adenosine is shown in blue, and 29-deoxyadenosine is shown in red.
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levels of adenosine or 29-deoxyadenosine do not differ from those
found in full-term babies. None of the patients with ADA
included in our study were born prematurely; however, it is
well known that high levels of toxic metabolites are already
present during fetal life,16 and low numbers of T lymphocytes and
29-deoxyadenosine triphosphate accumulation were found in the
blood of affected fetuses at 18 weeks’ gestation.16
ADA deficiency can sometimes manifest with partial enzyme
deficiency, with immunologic symptoms in adulthood, or with no
symptoms at all. We could not test neonatal blood spots obtained
from patients with adult-onset ADA-related immunodeficiency to
evaluate whether our test, which is performed at birth, can also
individuate this subpopulation of abnormal patients with ADA.
However, we could imagine 3 different hypotheses.
The first hypothesis involves patients in whom enzyme activity
is reduced and partial accumulation ofmetabolites is present. This
situation seems to be the most frequent in patients with partial
ADA deficiency.17-19 Metabolite accumulation is present even in
patients who are still asymptomatic, although at lower levelscompared with that seen in patients with complete ADA defi-
ciency. This situation is well known for other metabolic diseases
routinely screened at birth all over the world, such as hyperphen-
ylalaninemias. In the case of ADA deficiency, individuation of
partial metabolite accumulation would be even easier because
in healthy subjects the metabolite 29-deoxyadenosine is com-
pletely absent. Therefore its presence, even at very low blood
levels, would suggest a partial enzyme inactivity. Moreover, pa-
tients with late-onset ADA-SCID have been reported to have
29-deoxyadenosine levels that are at least 2-log higher than in
healthy control subjects,18 and therefore they could be easily
found.
The second hypothesis concerns patients with partial ADA
inactivity who retain absolutely normal detoxification ability.19
These patients might remain asymptomatic for all their lives
and be identified only by population screening of healthy adults.
We can imagine that if detoxification activity remains complete
and stable for all their lives, neither tandem mass spectrometric
methods nor methods based on TRECs can detect these subjects;
however, because they remain asymptomatic, to individuate them
J ALLERGY CLIN IMMUNOL
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disease.
The third hypothesis involves patients with completely nor-
mal enzyme activity at birth, decreasing over time and resulting
in the phenotype of immunodeficiency later in life. This
hypothesis seems the most unlikely; to our knowledge, serial
studies from birth to adulthood have not been performed in
patients with adult-onset ADA deficiency. However, even if
these patients could not be given diagnoses at birth because of
the presence of a complete metabolite detoxification, it would be
easy to make a diagnosis using the same tandem mass spectro-
metric method and at the same cost later in life as soon as
symptoms suggest the disease.
A trial for a population-based neonatal screening in Tuscany
was started in September 2010 to confirm the results of a larger
population and to perform early diagnosis of ADA-SCID.
Different from tests based on quantitation of TRECs, which
might provide indeterminate results because of poor DNA
recovery,1 the method described in the present research does
not seem to be affected by long-term storage or bad storage con-
ditions. Actually, even after 6 years, ADA metabolites are still
present at high levels, so that the method could unequivocally
individuate a patient with ADA-SCID born in 2004.
Different methods for measurement are used in clinical prac-
tice, ranging fromHPLC20 to capillary electrophoresis21 and even
reverse-phase HPLC with electrospray ionization tandem mass
spectrometry.22
However, all these methods are applied on urine samples and
are used when a clinical suspicion of immunodeficiency has
already been formulated because of the onset of severe infections.
All of them are time consuming and therefore not applicable
for screening purposes. In fact, we evaluated that the liquid
chromatographic2mass spectrometric method23 requires not less
than 20 minutes per sample. Moreover, urine is not available as a
biological matrix for screening purposes at birth.
ADA-SCID seems to have an incidence of 1:375,000 to
1:660,0004; by using the method described, the cost for individu-
ating 1 patient would be V3,750 to V6,600, and that amount is
probably lower than the cost of hospitalization of a patient with
ADA-SCID for his or her first infection. Indeed, the cost for hos-
pitalization in Italy is more than V500 per day in pediatric units
and more thanV1000 per day in intensive care units.24 Moreover,
it should be considered that the incidence of ADA-SCIDmight be
greater, being underestimated because of early death from infec-
tive disease or disorders caused by toxic metabolites. Actually, at
least 3 patients with ADA-SCID were born and resident in
Tuscany during the study period (2004-2009); given that in
the same period in Tuscany the number of live birth was
158,695,25 the incidence of ADA-SCID in Tuscany seems to be
1:53,000 or higher, more than previously thought.4 This cannot
be explained by the high rate of consanguinity, which, on the
contrary, is rare in Tuscany.
Cost-effectiveness analysis was out of the aim of the present
study; however, the extremely low cost per test suggests that this
test could be a worthwhile addition to newborn screening panels.
It has been recently reported in a cost-effectiveness study on
SCID screening that models are sensitive to the cost of the test and
that to maintain the cost at less than $100,000/quality-adjusted
year of life, the screening for SCID should cost less than $15 per
test.1 The cost per test using tandem mass spectrometry was less
than V0.01.It is without doubt that a method revealing all patients with
SCIDwith a unique test would provide a greater benefit; however,
at present, as reported by authors, even methods based on TREC
analysis through molecular biology cannot individuate all known
SCIDs and are undergoing refinement to improve specificity.1,15
The use of tandem mass spectrometry in the laboratories that
are already performing neonatal screening programs can make
possible a population-based newborn screening for ADA defi-
ciency and can add diagnosis for one of the most frequent form
of SCID at a negligible cost.
Clinical implications: The diagnosis of ADA-SCID can be per-
formed at birth on DBS samples by using tandem mass spec-
trometry within a neonatal program of screening with no
indeterminate or false-negative results and negligible cost.REFERENCES
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